MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-27 pm EDT 5-day change 1st Jan Change
3.92 USD +1.55% Intraday chart for MEI Pharma, Inc. +9.50% -32.41%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia CI
Stifel Adjusts Price Target on MEI Pharma to $7 From $8, Keeps Hold Rating MT
MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023 CI
Earnings Flash (MEIP) MEI PHARMA Posts Q1 Revenue $65.3M MT
MEI Pharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023 CI
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023 CI
MEI Pharma, Anson Funds and Cable Car Capital Enter into Cooperation Agreement CI
MEI Pharma, Inc. Announces Board Changes CI
MEI Pharma Solicits Proxies from Shareholders CI
Anson Funds Files Definitive Proxy Statement with Securities and Exchange Commission CI
Anson Funds hires Legion Partners' Gupta to build out activism strategy RE
Anson Advisors and Cable Car Capital Withdraws their Consent Solicitation CI
MEI Pharma Says Consent Solicitation by Anson Advisors, Cable Car Capital Would Create Significant Governance Disruption MT
MEI Pharma Issues Statement Regarding Anson Advisors and Cable Car?s Actions CI
Stifel Adjusts Price Target on MEI Pharma to $9 From $10, Maintains Hold Rating MT
MEI Pharma Rose in After-Hours Activity Tuesday Following Fiscal 2023 Results That Showed Higher Sales, Narrower Net Loss MT
Transcript : MEI Pharma, Inc., Q4 2023 Earnings Call, Sep 26, 2023
MEI Pharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Anson Advisors Solicits Proxies from Shareholders of MEI Pharma CI
North American Morning Briefing : Yield Surge -2- DJ
MEI Pharma Reports Institutional Purchase of 32,040 Shares Along With 6,000 Put Options MT
North American Morning Briefing : The Post-Fed Selloff Continues DJ
MEI Pharma Confirms Receipt of Director Nominations from Anson Group CI
Chart MEI Pharma, Inc.
More charts
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
3.92 USD
Average target price
23 USD
Spread / Average Target
+486.73%
Consensus
  1. Stock
  2. Equities
  3. Stock MEI Pharma, Inc. - Nasdaq
  4. News MEI Pharma, Inc.
  5. MEI Pharma Prices Common Stock Offering at $2.60 Per Share